A. Lepak

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
A. Lepak, Alex J Lepak, Alexander Lepak, Alexander J Lepak, Alex J. Lepak, Alex Lepak, Alexander J. Lepak, A. J. Lepak
Publication record
139 papers · 3,083 citations · H-index 34

PAPERS

Pharmacodynamic evaluation of BRII-693, a next-generation synthetic macrocyclic peptide antibiotic, in the neutropenic mouse thigh and lung infection models against gram-negative pathogens
20260 citationsauthor #1
Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development
20260 citationsauthor #1
311. Defining the magnitude of desirability of outcome ranking (DOOR) differences in effectiveness of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C/T) for multidrug-resistant (MDR) Pseudomonas aeruginosa infections in the United States (CACTUS)
20250 citationsauthor #23
The structure of the Vibrio natriegens 70S ribosome in complex with the proline-rich antimicrobial peptide Bac5(1–17)
20253 citationsauthor #4
Effectiveness of imipenem-relebactam for multidrug-resistant Pseudomonas aeruginosa in pneumonia and bloodstream infections in the United States (MIRAGE)
20250 citationsauthor #12
312. Impact of Patient Subgroups on the Efficacy of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C/T) for Multidrug-resistant (MDR) Pseudomonas aeruginosa infections in the United States (CACTUS)
20250 citationsauthor #25
MP27-19 IMPROVING ANTIBIOTIC STEWARDSHIP IN PATIENTS UNDERGOING URODYNAMIC TESTING
20250 citationsauthor #5
P-1214. Comparative Pharmacodynamics (PD) of Humanized Posaconazole and Isavuconazole Drug Exposures Against Wild-type and cyp51 Mutant Aspergillus fumigatus Clinical Strains in the Murine Invasive Pulmonary Aspergillosis (IPA) Model
20250 citationsauthor #1
The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics
202412 citationsauthor #4
In vivo pharmacodynamic evaluation of the novel nystatin derivative BSG005 in the invasive candidiasis and invasive pulmonary aspergillosis mouse models
20243 citationsauthor #1
In vivo pharmacodynamic characterization of a next-generation polyene, SF001, in the invasive pulmonary aspergillosis mouse model
20249 citationsauthor #1
Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study.
202430 citationsauthor #25
2552. Comparative Pharmacodynamic Evaluation of Commonly Utilized, Oral, 1st - 3rd Generation Cephalosporins against S. aureus and E. coli in the Mouse Thigh Infection Model
20231 citationsauthor #1
Neutropenic Fever–Associated Admissions Among Patients With Solid Tumors Receiving Chemotherapy During the COVID-19 Pandemic
20236 citationsauthor #6
Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches
20239 citationsauthor #1
Simplifying Recombinant Protein Production: Combining Golden Gate Cloning with a Standardized Protein Purification Scheme.
20234 citationsauthor #3
Validated Preclinical Murine Model for Therapeutic Testing against Multidrug Resistant Pseudomonas aeruginosa
20220 citationsauthor #9
Diagnostic and Therapeutic Utility of Positive Intravascular Catheter Tip Cultures
20224 citationsauthor #2
Validated Preclinical Mouse Model for Therapeutic Testing against Multidrug-Resistant Pseudomonas aeruginosa Strains
20226 citationsauthor #9
875. Guess Who’s Back: The Return of Seasonal Respiratory Viruses in the State of Wisconsin and Associated Changes in Antibiotic Prescribing for Respiratory Complaints
20220 citationsauthor #1
927. Successful Implementation of an Inpatient Fluoroquinolone (FQ) Pre-Authorization (PA) Program at a Tertiary Care Academic Center and Associated Changes in Antibiotic Use, Antibiogram Susceptibility, and Provider Behavioral Changes
20220 citationsauthor #5
Echinocandins
20219 citationsauthor #1
Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future
202159 citationsauthor #8
Viral Sequencing to Investigate Sources of SARS-CoV-2 Infection in US Healthcare Personnel
202130 citationsauthor #11
Viral sequencing reveals US healthcare personnel rarely become infected with SARS-CoV-2 through patient contact
202124 citationsauthor #10
COVID-19 in Health Care Personnel
20218 citationsauthor #1
Clinical Utility of Dual Anterior Nares and Oropharynx MRSA Screening PCR for Patients with Suspected Pneumonia – ERRATUM
20210 citationsauthor #5
Clinical Utility of Dual Anterior Nares and Oropharynx MRSA Screening PCR for Patients with Suspected Pneumonia
20211 citationsauthor #5
Implementation of telehealth antimicrobial stewardship through partnership of an academic medical center and a community hospital.
202112 citationsauthor #8
Letter to the Editor: Response to Maziade et al; Enhanced Clostridioides difficile infection prevention with a pharmacy-controlled policy that adds a three-strain Lactobacillus probiotic concomitantly to antibiotic therapy.
20210 citationsauthor #3
Decreasing ICU-associated Clostridioides difficile infection through fluoroquinolone restriction, the FIRST trial: a study protocol
20216 citationsauthor #5
Association of Changes in Seasonal Respiratory Virus Activity and Ambulatory Antibiotic Prescriptions With the COVID-19 Pandemic.
202128 citationsauthor #1
Reply to Maziade et al
20210 citationsauthor #3
Engineered PQQ-Dependent Alcohol Dehydrogenase for the Oxidation of 5-(Hydroxymethyl)furoic Acid
202021 citationsauthor #5
Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens
202036 citationsauthor #1
Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube.
202017 citationsauthor #12
Evaluation of a successful fluoroquinolone restriction intervention among high-risk patients: A mixed-methods study
20207 citationsauthor #7
Crystal structure of lanthanide-dependent alcohol dehydrogenase PedH from Pseudomonas putida KT2440
20200 citationsauthor #2
The two paralogous kiwellin proteins KWL1 and KWL1-b from maize are structurally related and have overlapping functions in plant defense
202012 citationsauthor #7
Implementation of infection control measures to prevent healthcare-associated transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2)
20207 citationsauthor #1
FDA Public Workshop Summary: Advancing Animal Models for Antibacterial Drug Development
202014 citationsauthor #12
Utility of Repeat Nasopharyngeal SARS-CoV-2 RT-PCR Testing and Refinement of Diagnostic Stewardship Strategies at a Tertiary Care Academic Center in a Low-Prevalence Area of the United States
20205 citationsauthor #1
Antibiotic prescribing patterns for coronavirus disease 2019 (COVID-19) in two emergency departments with rapid procalcitonin
202022 citationsauthor #5
2064. Applying Human Factors and Ergonomics to Inform a Successful Fluoroquinolone Restriction Intervention: A Mixed Methods Pilot Study
20191 citationsauthor #5
2182. Harnessing Direct-from-Blood MALDI-TOF (DBM) and Local Blood Stream Infection (BSI) Antibiogram Data to Direct Optimal Therapy for Gram-Negative Rod (GNR) Bacteremia
20191 citationsauthor #2
2162. Comparison of Plazomicin Disk Diffusion vs. Gradient Diffusion Susceptibility Testing Results Against Drug-Resistant Clinical Enterobacteriaceae Isolates
20191 citationsauthor #1
Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model
201921 citationsauthor #1
2153. Clinical Impact of Addition of Oropharynx MRSA PCR to Anterior Nares MRSA PCR for Patients Admitted with Pneumonia
20190 citationsauthor #5
In Vivo Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model
201932 citationsauthor #1
In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance.
201912 citationsauthor #7
In Vivo Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model
201912 citationsauthor #2
Impact of Triazole Therapeutic Drug Monitoring Availability and Timing
201922 citationsauthor #4
WCK 5222 (Cefepime-Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-Lactamase-Producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model
201926 citationsauthor #1
In Vivo Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model
201914 citationsauthor #1
APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis
201937 citationsauthor #2
Identification of Ureaplasma parvum as a Cause of Culture-Negative Septic Monoarthitis Using 16S rRNA Gene Sequencing
20193 citationsauthor #2
Decoupling of recombinant protein production from Escherichia coli cell growth enhances functional expression of plant Leloir glycosyltransferases
201923 citationsauthor #3
The Wrong Frame of Mind.
20182 citationsauthor #2
406. Achievement of Clinical Isavuconazole (ISA) Serum and Plasma Drug Concentrations in Two Patients With Isavuconazonium Capsules Administered via Nasogastric Feeding Tube (NGT)
20180 citationsauthor #6
1383. In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of NOSO-502, a First-in-Class Odilorhabdin Antibiotic, Against E. coli (EC) and K. pneumoniae (KPN) in the Murine Neutropenic Thigh Model
20181 citationsauthor #2
In Vivo Pharmacodynamic Characterization of a Novel Antibiotic Odilorhabdins , 1 NOSO-502 against Escherichia coli and Klebsiella pneumoniae in a Murine 2 Thigh Infection Model 3 4
20180 citationsauthor #2
New flavanol O-glycosides in grape and wine.
201838 citationsauthor #5
In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model
201867 citationsauthor #2
In Vivo Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model
201811 citationsauthor #2
Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model
201865 citationsauthor #1
β-Glucosyl Fluoride as Reverse Reaction Donor Substrate and Mechanistic Probe of Inverting Sugar Nucleotide-Dependent Glycosyltransferases
20188 citationsauthor #1
Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae
201817 citationsauthor #1
Biochemical Characterization and Mechanistic Analysis of the Levoglucosan Kinase from Lipomyces starkeyi
201814 citationsauthor #5
In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model
201736 citationsauthor #2
Long-Term Prognosis of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia at a Tertiary Care Hospital in the United States (US)
20171 citationsauthor #1
Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus
201728 citationsauthor #1
Pharmacodynamic Optimization for the Treatment of Invasive Candida auris Infection
201782 citationsauthor #1
In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model
20174 citationsauthor #1
Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design
201753 citationsauthor #1
Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters
201734 citationsauthor #10
In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model
201745 citationsauthor #1
In vivo infection models in the pre‐clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents
201746 citationsauthor #2
In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa
201790 citationsauthor #1
Isavuconazole: Has It Saved Us? A Pharmacotherapy Review and Update on Clinical Experience
20172 citationsauthor #3
In vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Staphylococcus aureus (SA) in the Murine Thigh Infection Model
20176 citationsauthor #1
Glycosyltransferase cascades for natural product glycosylation: Use of plant instead of bacterial sucrose synthases improves the UDP-glucose recycling from sucrose and UDP.
201739 citationsauthor #2
Impact of Low Procalcitonin Results on Antibiotic Administration in Hospitalized Patients at a Tertiary Care Center
20164 citationsauthor #4
In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus
201610 citationsauthor #1
Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Provide Dose Selection Support for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP)
20162 citationsauthor #5
Solubility Enhancement by Site-Selective Polyphenol Glucosylation
20160 citationsauthor #1
In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model
201644 citationsauthor #1
Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents.
201696 citationsauthor #2
Exploiting the biocatalytic potential of glycosyltransferases through in situ sugar donor recycling
20160 citationsauthor #3
Animal Models to Evaluate Anti-infective Pharmacodynamics
20162 citationsauthor #1
Screening of recombinant glycosyltransferases reveals the broad acceptor specificity of stevia UGT-76G1.
201645 citationsauthor #4
Improving the Water Solubility of Polyphenols through Site-Selective Enzymatic Glucosylation
20160 citationsauthor #1
Top 1% of Inpatients Administered Antimicrobial Agents Comprising 50% of Expenditures: A Descriptive Study and Opportunities for Stewardship Intervention
20169 citationsauthor #5
CREATING A WATER-SOLUBLE RESVERATROL-BASED ANTIOXIDANT THROUGH SITE-SELECTIVE ENZYMATIC GLUCOSYLATION
20161 citationsauthor #1
Comparative In vivo Pharmacokinetics/Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh Infection Model Against Staphylococcus aureus
20160 citationsauthor #1
Sucrose synthase: a unique glycosyltransferase enroute to biocatalytic process development
20150 citationsauthor #3
8:00 MEDICAL APPLICATIONS OF ANTIMICROBIAL PROPHYLAXIS: MORE THAN YOU'D THINK
20150 citationsauthor #3
Pharmacodynamic (PD) Activity of Dalbavancin against VISA Staphylococcus aureus (SA) isolates in the Neutropenic Murine Thigh Infection Model
20150 citationsauthor #1
Creating a Water‐Soluble Resveratrol‐Based Antioxidant by Site‐Selective Enzymatic Glucosylation
201575 citationsauthor #1
Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target
201535 citationsauthor #1
Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice
201510 citationsauthor #1

TIMELINE

1988 0 citations

2005 56 citations

2006 150 citations

2008 3 citations

2009 175 citations

2010 220 citations

2011 59 citations

2012 182 citations

2013 225 citations

2014 175 citations

2015 331 citations

2016 213 citations

2017 466 citations

2018 223 citations

2019 205 citations

2020 141 citations

2021 177 citations

2022 10 citations

2023 20 citations

2024 54 citations

2025 3 citations

2026 0 citations

Unknown 0 citations

A. Lepak

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT